Abstract
Systemic amyloidoses are caused by misfolding-prone proteins that polymerize in tissues, causing organ dysfunction. Since proteins are etiological agents of these diseases, proteomics was soon recognized as a privileged instrument for their investigation. Mass spectrometry-based proteomics has acquired a fundamental role in management of systemic amyloidoses, being now considered a gold standard approach for amyloid typing. In parallel, approaches for analyzing circulating amyloid precursors have been developed. Moreover, differential and functional proteomics hold promise for identifying novel biomarkers and clarifying disease mechanisms. This review discusses recent proteomics achievements in systemic amyloidoses, providing a perspective on its present and future applications.
| Original language | English |
|---|---|
| Pages (from-to) | 4-10 |
| Number of pages | 7 |
| Journal | EuPA Open Proteomics |
| Volume | 11 |
| DOIs | |
| Publication status | Published - Jun 1 2016 |
Fingerprint
Keywords
- Amyloidogenic proteins
- Amyloidosis
- Clinical proteomics
- Proteotoxicity
- Tissue biomarkers
ASJC Scopus subject areas
- Biochemistry
Cite this
Systemic amyloidoses and proteomics : The state of the art. / Lavatelli, Francesca; di Fonzo, Andrea; Palladini, Giovanni; Merlini, Giampaolo.
In: EuPA Open Proteomics, Vol. 11, 01.06.2016, p. 4-10.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Systemic amyloidoses and proteomics
T2 - The state of the art
AU - Lavatelli, Francesca
AU - di Fonzo, Andrea
AU - Palladini, Giovanni
AU - Merlini, Giampaolo
PY - 2016/6/1
Y1 - 2016/6/1
N2 - Systemic amyloidoses are caused by misfolding-prone proteins that polymerize in tissues, causing organ dysfunction. Since proteins are etiological agents of these diseases, proteomics was soon recognized as a privileged instrument for their investigation. Mass spectrometry-based proteomics has acquired a fundamental role in management of systemic amyloidoses, being now considered a gold standard approach for amyloid typing. In parallel, approaches for analyzing circulating amyloid precursors have been developed. Moreover, differential and functional proteomics hold promise for identifying novel biomarkers and clarifying disease mechanisms. This review discusses recent proteomics achievements in systemic amyloidoses, providing a perspective on its present and future applications.
AB - Systemic amyloidoses are caused by misfolding-prone proteins that polymerize in tissues, causing organ dysfunction. Since proteins are etiological agents of these diseases, proteomics was soon recognized as a privileged instrument for their investigation. Mass spectrometry-based proteomics has acquired a fundamental role in management of systemic amyloidoses, being now considered a gold standard approach for amyloid typing. In parallel, approaches for analyzing circulating amyloid precursors have been developed. Moreover, differential and functional proteomics hold promise for identifying novel biomarkers and clarifying disease mechanisms. This review discusses recent proteomics achievements in systemic amyloidoses, providing a perspective on its present and future applications.
KW - Amyloidogenic proteins
KW - Amyloidosis
KW - Clinical proteomics
KW - Proteotoxicity
KW - Tissue biomarkers
UR - http://www.scopus.com/inward/record.url?scp=84959345894&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959345894&partnerID=8YFLogxK
U2 - 10.1016/j.euprot.2016.02.003
DO - 10.1016/j.euprot.2016.02.003
M3 - Article
AN - SCOPUS:84959345894
VL - 11
SP - 4
EP - 10
JO - EuPA Open Proteomics
JF - EuPA Open Proteomics
SN - 2212-9685
ER -